On November 21, 2019 Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, reported that it will present preclinical data for the company’s programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61st Annual American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla (Press release, Beam Therapeutics, NOV 21, 2019, View Source [SID1234551565]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the new data being presented in a poster at ASH (Free ASH Whitepaper) are as follows:
Title: Complementary base editing approaches for the treatment of sickle cell disease and
Beta-thalassemia
Date & Time: Sunday, December 8, 2019, 6:00-8:00 p.m. ET
Poster Session: 801 – Gene Therapy and Transfer: Poster II
Location: Orange County Convention Center, Hall B
Presenter: Ling Lin, Ph.D., senior scientist II, Beam Therapeutics